This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Greatbatch, Inc. Reports 2012 Fourth Quarter And Full Year Results

Despite the GAAP loss for the 2012 fourth quarter and year, cash flows from operations for the fourth quarter and full-year of 2012 were approximately $25 million and $65 million, respectively as a significant portion of the charges recorded in 2012 were non-cash in nature. During the fourth quarter and full-year of 2012, the Company repaid $8 million and $22 million, respectively, of long-term debt.

Product Line Sales                
The following table summarizes the Company’s sales by major product lines (dollars in thousands):
   
2012 2011 % 2012 % 2012 2011 %

Product Line

4th Qtr. 4th Qtr. Chg. 3rd Qtr. Chg. Year Year Chg.
Implantable Medical
Cardiac/Neuromodulation $ 73,718 $ 77,198 -5 % $ 80,246 -8 % $ 309,124 $ 303,690 2 %
Vascular 14,189 12,459 14 % 13,674 4 % 51,980 45,098 15 %
Orthopaedic   30,982   31,635 -2 %   27,173 14 %   122,061   140,277 -13 %
Total 118,889 121,292 -2 % 121,093 -2 % 483,165 489,065 -1 %
Electrochem
Portable Medical 22,313 3,504 N/A 20,219 10 % 81,659 9,609 N/A
Energy/Environmental 15,605 13,121 19 % 16,192 -4 % 67,046 58,934 14 %
Other   2,379   3,829 -38 %   3,836 -38 %   14,307   11,214 28 %
Total   40,297   20,454 97 %   40,247 0 %   163,012   79,757 104 %
$ 159,186 $ 141,746 12 % $ 161,340 -1 % $ 646,177 $ 568,822 14 %

Implantable Medical

In comparison to the prior year, cardiac and neuromodulation sales for the fourth quarter of 2012 decreased 5% but increased 2% for the full-year. During 2012, cardiac and neuromodulation sales benefited from further adoption of our Q series batteries and customer market share shifts partially offset by the timing of customer inventory builds and product launches. Cardiac and neuromodulation revenue growth exceeded our expectations during 2012 but management remains cautiously optimistic over the short-term prospects of this product line given the ongoing challenges surrounding key OEM customers. However, our longer term outlook remains optimistic as we continue to see an increased pace of product development opportunities from our cardiac customers. Management believes that this, combined with our increased focus on sales and marketing, will allow the Company to grow this product line faster than the underlying market.

6 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,036.07 -90.05 -0.50%
S&P 500 2,107.91 -12.88 -0.61%
NASDAQ 5,070.4880 -27.4880 -0.54%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs